💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Chlormezanone

CHEMBL1200714 Phase 4 Disetujui Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
273.7 g/mol
LogP
1.1
Phase
4

A muscle relaxant and anxiolytic drug that was used for the short-term relief of muscle spasm and anxiety. It was withdrawn from worldwide markets in the 1990s due to reports of severe cutaneous reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome. It is no longer available clinically.

Berat Molekul

273,7400 g/mol

LogP

1,10

TPSA

62,80 Ų

Lipinski RO5

Lulus

Area Terapeutik

Pain Management Schizophrenia Bipolar Disorder Chronic Pain

Mekanisme Kerja

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Struktur 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C11H12ClNO3S

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Ikatan yang Dapat Dirotasi

                        
1

                    

                    
                    
                    

                        
Atom Berat

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Pertanyaan yang Sering Diajukan

                

                    
                    

                        
                        

                            
A muscle relaxant and anxiolytic drug that was used for the short-term relief of muscle spasm and anxiety. It was withdrawn from worldwide markets in the 1990s due to reports of severe cutaneous reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome. It is no longer available clinically.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Chlormezanone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200714.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2717.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Penyangkalan Medis

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.